BPF invests 3.7 million euros in Chrysea Labs, through the 200M Fund
Chrysea is a synthetic biology company developing high-value and difficult to source natural products, backed by clinical study evidence, with the goal of providing a healthy life path and aging process.
The lead project to be developed through this partnership is a naturally occurring small molecule which has substantial pre-clinical evidence of benefit in maintaining cardiovascular, cognitive and immune function in ageing individuals.
“The molecules developed by Chrysea are naturally occurring metabolites that induce autophagy in our bodies, helping clear out cellular debris and stimulate cellular regeneration essential for healthy ageing”, said Colin Watts, Chairman of the JuvLife division focused on developing natural and nutritional therapies to promote healthy ageing in individuals.
“To date, this molecule has not been available in a pure form and in sufficient quantity nor quality to develop and market a highly pure and reliable product, produced and developed in a consistent and reproducible way. Chrysea’s breakthrough processes have created this exciting opportunity”, said Pedro de Noronha Pissarra, CEO of Chrysea Labs.
For Beatriz Freitas, CEO of Banco Português de Fomento, the managing entity of the 200M Fund, “it is with great enthusiasm that the 200M Fund supports Chrysea’s project of developing precision nutritional interventions supported by rigorous clinical research, aimed at successful ageing and a healthy lifespan. Chrysea and its team of seasoned experts in life-sciences, from synthetic biology to nutrition, metabolism, and clinical research activities, represent the talent and expertise that exists in the Portuguese scientific community and that contributes to innovating and energizing the entrepreneurial ecosystem. With this investment, BPF makes another important contribution to supporting and strengthening the competitiveness of Portuguese startups”.
Find out about the companies invested by the 200M Fund here.
